Gene Therapy Encoding Cell Cycle Factors to Treat Chronic Ischemic Heart Failure in Rats

Scientists demonstrated, for the first time, that TNNT2-4Fpolycistronic-NIL gene therapy induces cardiomyocyte cell cycle re-entry in chronic ischemic heart failure and improves left ventricular function and that this salubrious effect is sustained for at least four months.